Does the French general practitioner correctly investigate and treat osteoporosis?

Clinical Rheumatology

Volumn 17, Issue 2, 1998, Pages 139-143

  Laroche, M ^a   Mazieres B ^a  

^a CHU RANGUEIL   (France)

Author keywords

General practitioner; Osteoporosis investigations; Treatment

Indexed keywords

CALCITONIN; CALCIUM; COLECALCIFEROL; ERGOCALCIFEROL; ESTROGEN; ETIDRONIC ACID; FLUORIDE; GESTAGEN; PHOSPHORUS;

ADULT; AGED; ARTICLE; BONE DENSITY; DUAL ENERGY X RAY ABSORPTIOMETRY; ESTROGEN THERAPY; FEMALE; FRACTURE; FRANCE; GENERAL PRACTICE; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; OSTEOPOROSIS; PRESCRIPTION; PRIORITY JOURNAL; SPINE RADIOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; DISEASE MANAGEMENT; FAMILY PRACTICE; FEMALE; FRANCE; HUMANS; MIDDLE AGED; OSTEOPOROSIS; QUESTIONNAIRES;

EID: 0031799910     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01452261     Document Type: Article

References (21)

1. Melton LJ, Chrischilles EA, Cooper C, Lane AW, Riggs BL. How many women have osteoporosis? J Bone Mineral Res 1992;7:1005-10.
2. Consensus Development Conference. Diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 1993;94:646-50.
3. Laroche M. Examen et surveillance d'une patiente présentant une ostéoporose. Tempo Médical 1993;483:19-20.
4. Laroche M. Reconnaitre et traiter un tassement vertébral vu en ville. Tempo Médical 1993;483:21-3.
5. Roux C. Tassement vertébral. La Revue du Praticien. 1995; 9:1115-9.
6. Marcelli C. Les ostéoporoses secondaires. La Revue du Praticien 1995;9:1125-32.
7. Rapport du comité scientifique du GRIO. Intérêt et indications cliniques des mesures de masse osseuse par absorptiométrie biphotonique àrayons x. Rev Rhum 1994;7-8 (special issue).
8. Nagant de Deuxchaines C. L'ostéoporose d'involution. Impact Médecin 1990;54:33-5.
9. Alexandre C. Traitement de l'ostéoporose. Tempo Médical 1993;3:1-4.
10. Sebert JL, Glowinski J, Marcelli C, Acquaviva P. Ostéoporose aui quotidien. Le Quotidien du médecin 1992;5019:1-13.
11. Ribot C, Trémollieres F. Pouillès JM. Traitement hormonal et prévention précoce et tardive de l'ostéoporose. Press Med 1995;24:999-1002.
12. Marx CW, Dailey GE, Cheney C. Do oestrogens improve bone mineral density in osteoporotic women over age 65. J Bone Mineral Res 1992;7:1275-9.
13. Lufkin EG, Whaner HW, O'Fallon WM, et al. Treatment of postmenopausal osteoporosis with trans-dermal oestrogens. Ann Intern Med 1992;117:1-9.
14. Reginster JY. Calcitonin for prevention and treatment of osteoporosis. Am J Med 1993;95:45-8.
15. Rico H, Hernadez HR, Revilla M. Gomez-Castresara F. Salmon calcitonin reduces vertebral fracture rate in post-menopausal crush fracture syndrome. Bone Miner 1992;16:131-8.
16. Ribot C, Pouillès JM, Trémollieres F. A propos de la définition densitométrique de l'ostéoporose. Rev Rhum 1995;9:579-81.
17. Alexandre C. L'ostéoporose en question. Rev Rhum 1993; 60:407-1.
18. Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with post menopausal osteoporosis. N Engl J Med 1990;332:1265-71.
19. Watts NB, Harris ST, Genant HK. et al. Intermittent cyclical etidronate treatment of post menopausal osteoporosis N Engl J Med 1990;323:73-9.
20. Mamelle N, Meunier PJ, Dusan R, et al. Risk benefit ratio of sodium fluoride treatment in primary osteoporosis. Lancet 1988;ii:356-65.
21. Riggs BL, Hodgson SF, O'Fallon WM. et al. Effects of fluoride treatment on the fracture rate in post menopausal women with osteoporosis. N Engl J Med 1990;322:802-9.